Key Drivers
- High margins
- Large cash buffer
- Low reinvestment
AIAI Summary
CPRX has shifted from a binary biotech into a cash-rich specialty pharma where valuation now hinges on sustained AGAMREE/FIRDAPSE commercial execution to offset FYCOMPA erosion and favorable patent-litigation outcomes—monitor promoted-product growth, payer collections/receivables, and key IP rulings as the definitive catalysts for re-rating or downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Large cash buffer
- •Low reinvestment
CPRX is highly profitable and cash-rich with minimal leverage and strong cash generation, but weak ROIC and very low reinvestment raise concerns about capital deployment and sustainable growth. #cash-rich #low-reinvestment
Price Behavior
Key Price Behavior Insights:
- •Below last-month average
- •Downward momentum
- •Defense near $23.2
Price shows mild downtrend—closing below its last-month average with RSI ~39, favoring short bias toward the low-$22s unless it reclaims resistance near $24.7–$24.9.
Close below last-month average and potential break under $22.33 would confirm further weakness
Sentiment & News
Key News Insights:
- •Record revenues
- •2026 guidance
- •Fycompa competition
Catalyst reported record Q4 and FY-2025 results with 2026 revenue guidance of $615–$645M driven by FIRDAPSE and AGAMREE growth despite emerging generic pressure on Fycompa.
Strong commercial momentum and bullish analyst attention support upside, but investor risk remains tied to Fycompa generic erosion
Similar Companies in Healthcare
Other companies in the same sector with AI ratings